Vigneshwaran Venkatesan
Overview
Explore the profile of Vigneshwaran Venkatesan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
59
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Chandraprabha P, Azhagiri M, Venkatesan V, Magis W, Prasad K, Suresh S, et al.
Stem Cell Res Ther
. 2024 Dec;
15(1):504.
PMID: 39736768
Background: Sickle cell disease (SCD) and β-thalassemia patients with elevated gamma globin (HBG1/G2) levels exhibit mild or no symptoms. To recapitulate this natural phenomenon, the most coveted gene therapy approach...
2.
Prasad K, Devaraju N, George A, Ravi N, Paul J, Mahalingam G, et al.
Mol Ther Nucleic Acids
. 2024 May;
35(2):102205.
PMID: 38817682
β-thalassemia/HbE results from mutations in the β-globin locus that impede the production of functional adult hemoglobin. Base editors (BEs) could facilitate the correction of the point mutations with minimal or...
3.
Srikant K, Soni A, Pradhan S, Gulia A, Sandeep B, Kafley R, et al.
Cureus
. 2024 Jan;
15(12):e50864.
PMID: 38259399
Methods: Fourteen cases of NFFs presented to Kalinga Institute of Medical Sciences, Bhubaneswar, India, between January 2020 and June 2022 were recruited for the study. After preoperative evaluation and explanation...
4.
Venkatesan V, Christopher A, Rhiel M, Azhagiri M, Babu P, Walavalkar K, et al.
Mol Ther Nucleic Acids
. 2023 May;
32:671-688.
PMID: 37215154
Reactivation of fetal hemoglobin (HbF) is a commonly adapted strategy to ameliorate β-hemoglobinopathies. However, the continued production of defective adult hemoglobin (HbA) limits HbF tetramer production affecting the therapeutic benefits....
5.
Lohchania B, Christopher A, Arjunan P, Mahalingam G, Kathirvelu D, Prasannan A, et al.
Front Bioeng Biotechnol
. 2023 Jan;
10:1031049.
PMID: 36698628
The CRISPR/Cas9 system holds great promise in treating genetic diseases, owing to its safe and precise genome editing. However, the major challenges to implementing the technology in clinics lie in...
6.
Venkatesan V, Christopher A, Karuppusamy K, Babu P, Alagiri M, Thangavel S
J Vis Exp
. 2022 Aug;
(186).
PMID: 36036597
CRISPR/Cas9 is a highly versatile and efficient gene-editing tool adopted widely to correct various genetic mutations. The feasibility of gene manipulation of hematopoietic stem and progenitor cells (HSPCs) in vitro...
7.
Bagchi A, Devaraju N, Chambayil K, Rajendiran V, Venkatesan V, Sayed N, et al.
Sci Rep
. 2022 Aug;
12(1):14033.
PMID: 35982069
Numerous genes exert multifaceted roles in hematopoiesis. Therefore, we generated novel lineage-specific RNA interference (RNAi) lentiviral vectors, H23B-Ery-Lin-shRNA and H234B-Ery-Lin-shRNA, to probe the functions of these genes in erythroid cells ...
8.
Karuppusamy K, Demosthenes J, Venkatesan V, Christopher A, Babu P, Azhagiri M, et al.
Front Immunol
. 2022 Apr;
13:792684.
PMID: 35359982
Transplantation of allogenic hematopoietic stem and progenitor cells (HSPCs) with C-C chemokine receptor type 5 (CCR5) Δ32 genotype generates HIV-1 resistant immune cells. CCR5 gene edited autologous HSPCs can be...
9.
Rapaka H, Manturthi S, Arjunan P, Venkatesan V, Thangavel S, Marepally S, et al.
ACS Appl Bio Mater
. 2022 Mar;
5(4):1489-1500.
PMID: 35297601
Intracellular delivery of biomolecules using non-viral vectors critically depends on the vectors' ability to allow the escape and release of the contents from the endosomes. Prior findings demonstrated that aromatic/hydrophobic...
10.
Azhagiri M, Babu P, Venkatesan V, Thangavel S
Stem Cell Res Ther
. 2021 Sep;
12(1):500.
PMID: 34503562
The advent of next-generation genome engineering tools like CRISPR-Cas9 has transformed the field of gene therapy, rendering targeted treatment for several incurable diseases. Hematopoietic stem and progenitor cells (HSPCs) continue...